We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Devicemakers Should Prepare Now for eMDR Submissions

Devicemakers Should Prepare Now for eMDR Submissions

April 10, 2015

Devicemakers should submit new electronic Medical Device Reports several days before the deadline or risk being considered late under U.S. FDA requirements that take effect Aug. 14.

The extra time is necessary because the date of receipt will depend on the FDA telling the firm that the form was successfully loaded into the Center for Devices and Radiological Health’s database, says Deborah Kacera, a regulatory and industry strategist with Pilgrim Solutions.

The new system requires three electronic acknowledgements. The first contains the regulatory date that the FDA received the eMDR and lets the sender know if the form was received on time. The second informs the sender that the report passed through the electronic gateway and is on its way to the CDRH server, and the third tells the sender that the file has been accepted.

“If acknowledgement three comes back and says the submission failed, it will tell you what failed,” Kacera says. The sender must correct the failure, which may include a format or code issue, and resubmit the eMDR, restarting the process and requiring three new acknowledgements, she adds. Once approved, the file moves to the Manufacturer and User Facility Device Experience, or MAUDE, database.

Kacera, who spoke in a recent FDAnews webinar, also reviewed the steps devicemakers must take before posting an eMDR. The first is to generate an electronic file and send it to the FDA’s electronic submission gateway.

Next, companies need to submit a Non-Repudiation Letter affirming that the signer’s digital signature is equivalent to a handwritten signature. U.S. agents or consultants sending eMDRs for customers will need an authorization letter in addition to the Non-Repudiation Letter, Kacera says. A digital certificate that defines the sender as the company’s submitter must be sent to the FDA as well.

To assist companies, the FDA has free downloadable software that generates an eMDR file, she notes. When the required documents and software are in place, firms must do basic connectivity tests with the ESG. The agency will provide tests so that devicemakers can track submissions through the process to the MAUDE database.

Kacera recommends that during testing, companies create a “mock go-live” and attempt to submit eMDRs. Find it out ahead of time if the eMDR was done properly, she says, “because once you’ve gone live, you can’t go back.” — Charlotte Astor

Regulatory Affairs Postmarket Safety

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • AstraZeneca

    AstraZeneca Withdraws Imfinzi’s Bladder Cancer Indication

  • CE mark

    Cue Health’s COVID-19 Test Receives CE Mark

  • Sanofi-Regeneron_Logos.png

    Sanofi’s and Regeneron’s Libtayo Wins FDA Approval for NSCLC

  • PerkinElmer logo

    PerkinElmer’s Rapid Point-of-Care COVID-19 Test Cleared in Europe

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing